Moreover, we described a synergistic effect induced by combining the TRPV1 activator OLDA with imatinib in stimulating both DNA breaks and apoptosis in CML. The gene discussed is TRPV1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.